Show simple item record

dc.contributor.authorAhmadi, Y
dc.contributor.authorGhorbanihaghjo, A
dc.contributor.authorNaghi-Zadeh, M
dc.contributor.authorYagin, NL
dc.date.accessioned2018-08-26T07:11:27Z
dc.date.available2018-08-26T07:11:27Z
dc.date.issued2018
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/44317
dc.description.abstractStatins, inhibitors of hydroxy methyl glutaryl coenzyme-A (HMG-CoA) reductase, are the most widely used drugs for treating hypercholesterolemia. However, statins can cause disabling myopathy as their main adverse effect. Several molecular mechanisms underlie the statin-induced myopathy including the decrease in the levels of essential mevalonate and cholesterol derivatives. This review discusses a further mechanism involving the loss of other anti-oxidant defenses besides ubiquinone (Co-Q) in skeletal muscles which produce a significant amount of reactive oxygen species (ROS). Therefore, to maintain their function, skeletal muscles need a high level of anti-oxidants.
dc.language.isoEnglish
dc.relation.ispartofINFLAMMOPHARMACOLOGY
dc.subjectCholesterol
dc.subjectMyopathy
dc.subjectOxidative stress
dc.subjectStatins
dc.subjectUbiquinone
dc.titleOxidative stress as a possible mechanism of statin-induced myopathy
dc.typeReview
dc.citation.volume26
dc.citation.issue3
dc.citation.spage667
dc.citation.epage674
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.1007/s10787-018-0469-x


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record